Moderna, Inc. (MRNA)
Top Stock Movers Now: Viking, Moderna, Uber Technologies, and More
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Moderna: After A Crash From $500 To $25, I'm Buying This "Call Option" On Pandemics And Cancer
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportunities could drive a significant rebound, despite near-term losses and vaccine skepticism. Moderna's strong balance sheet, insider buying, and promising oncology candidates add to my conviction for a small, speculative position.
Why Moderna Merged Its Tech and HR Departments
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
Moderna faces long-term threat from NIH's universal vaccine initiative, Jefferies says
Moderna Inc (NASDAQ:MRNA, ETR:0QF) could face a longer-term threat from a newly announced US government initiative to develop universal vaccines for pandemic-prone viruses, analysts at Jefferies said on Friday. The National Institutes of Health (NIH) unveiled plans this week to build a next-generation vaccine platform aimed at creating broad-spectrum, long-lasting protection against viruses like avian flu and coronaviruses.
Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combination flu/COVID-19 vaccine delay its market entry, adding to the company's challenges amid strong competition from other drugmakers. Despite cost-cutting efforts, Moderna's financial health is strained, with high costs and low margins, leading to a downgrade to "Sell" or "market underperform."
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Cory Kasimov - Evercore ISI Courtney Breen - Bernstein Dick Gottfred - William Blair Gena Wang - Barclays Operator Good day, and thank you for standing by. Welcome to the Moderna First Quarter 2025 Conference Call.
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago.
Moderna Posts Loss, Citing Seasonality of Respiratory Business
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Countdown to Moderna (MRNA) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
